Cargando…

Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada

BACKGROUND: The current Canadian Cardiovascular Society antiplatelet therapy guidelines recommend the use of ticagrelor or prasugrel over clopidogrel as first-line platelet P2Y12 receptor antagonists for treatment of moderate- to high-risk acute coronary syndromes. Recently, Effient (prasugrel [Eli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lordkipanidzé, Marie, Marquis-Gravel, Guillaume, Tanguay, Jean-François, Mehta, Shamir R., So, Derek Y.F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209390/ https://www.ncbi.nlm.nih.gov/pubmed/34169260 http://dx.doi.org/10.1016/j.cjco.2020.11.021

Ejemplares similares

Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
por: Jourdi, Georges, et al.
Publicado: (2022)

Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines
por: Jourdi, Georges, et al.
Publicado: (2022)

Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview
por: Hillegass, William B, et al.
Publicado: (2011)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018)

Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
por: Alexopoulos, Dimitrios, et al.
Publicado: (2013)

Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy
por: Reid, Christopher, et al.
Publicado: (2020)

Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
por: Kiebist, Jan, et al.
Publicado: (2021)

Head-to-Head Comparison of Consensus-Recommended Platelet Function Tests to Assess P2Y(12) Inhibition—Insights for Multi-Center Trials
por: Bélanger, Jean-Christophe, et al.
Publicado: (2020)

Antiplatelet Effect of Single Antiplatelet Therapy With Prasugrel and Oral Anticoagulation After Stent Implantation in a Rabbit Arteriovenous Shunt Model
por: Torii, Sho, et al.
Publicado: (2021)

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
por: Laredo, Viviana, et al.
Publicado: (2020)

CORRIGENDUM: Antiplatelet Effect of Single Antiplatelet Therapy With Prasugrel and Oral Anticoagulation After Stent Implantation in a Rabbit Arteriovenous Shunt Model
por: Torii, Sho, et al.
Publicado: (2022)

Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study
por: Winter, Max-Paul, et al.
Publicado: (2019)

Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
por: Ki, You-Jeong, et al.
Publicado: (2021)

Antiplatelet effects of aspirin vary with level of P2Y(12) receptor blockade supplied by either ticagrelor or prasugrel
por: KIRKBY, N S, et al.
Publicado: (2011)

Vasodilator-stimulated phosphoprotein (VASP) is not a major mediator of platelet aggregation, thrombogenesis, haemostasis, and antiplatelet effect of prasugrel in rats
por: Ito, Yusuke, et al.
Publicado: (2018)

Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel
por: Kitazono, Takanari, et al.
Publicado: (2018)

Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis
por: Bainey, Kevin R., et al.
Publicado: (2023)

Prasugrel in critically ill patients
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
por: Jourdi, Georges, et al.
Publicado: (2021)

Effects of Vonoprazan on the Antiplatelet Function of Prasugrel Assessed by the VerifyNow P2Y(12) Assay in Patients With Coronary Artery Disease
por: Koga, Seiji, et al.
Publicado: (2020)

Reduction of thromboembolic complications during the endovascular treatment of unruptured aneurysms by employing a tailored dual antiplatelet regimen using aspirin and prasugrel
por: Higashiguchi, Saeko, et al.
Publicado: (2021)

Erratum: Correction of Text in the Article “Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI”
por: Ki, You-Jeong, et al.
Publicado: (2022)

Variability of response on prophylactic prasugrel for endovascular treatment of intracranial aneurysms: Clinical implications
por: Hong, Noah, et al.
Publicado: (2023)

Effects of switching from clopidogrel to prasugrel at the chronic phase after coronary stenting on antiplatelet action and vascular endothelial function: Switch-Pras study
por: Masuyama, Taiki, et al.
Publicado: (2020)

Continue or Discontinue Dual Antiplatelet Therapy in Major Surgical or Endoscopic Procedures
por: Cheon, Young Koog
Publicado: (2013)

Prasugrel-Induced Hypersensitivity Skin Reaction
por: Kim, Soo-Han, et al.
Publicado: (2014)

Prasugrel for Secondary Prevention of Thrombotic Stroke
por: Yagita, Yoshiki
Publicado: (2023)

Review of Prasugrel for the Secondary Prevention of Atherothrombosis
por: Spinler, Sarah A., et al.
Publicado: (2009)

Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry
por: Goldstein, Patrick, et al.
Publicado: (2016)

Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis
por: Wang, Zhe, et al.
Publicado: (2020)

Comparison of lower loading dose of prasugrel with conventional loading dose of prasugrel in Indian patients undergoing percutaneous coronary interventions
por: Kumari, Priti, et al.
Publicado: (2018)

Very late bioresorbable scaffold thrombosis after discontinuation of dual antiplatelet therapy
por: Karanasos, Antonios, et al.
Publicado: (2014)

Discontinuation of antiplatelet therapy after stent-assisted coil embolization for cerebral aneurysms
por: Kim, Tae Gon
Publicado: (2023)

Platelet Quiescence in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Bypass Graft Surgery
por: Sarathy, Kiran, et al.
Publicado: (2021)

Prasugrel for the treatment of patients with acute coronary syndrome
por: Marzot, Filippo, et al.
Publicado: (2009)

TRITON and Beyond: New Insights into the Profile of Prasugrel
por: Jakubowski, Joseph A, et al.
Publicado: (2012)

Eversion endarterectomy under full prasugrel treatment
por: Kotsis, Thomas, et al.
Publicado: (2017)

Low-Dose Prasugrel in Treatment of Cerebral Aneurysms
por: Kang, Hyun-Seung
Publicado: (2018)

Critical Review of Prasugrel for Formulary Decision Makers
por: Schafer, Jeremy
Publicado: (2009)

The Usefulness of Prasugrel as Rescue Medication in Neuroendovascular Therapy
por: Niimi, Jun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_89n9b8d1gq4o1glbehbfa1vjgu